Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears

Executive Summary

The pharma is confident in its current discounting to protect Remicade market share in the US – it still plans to focus on a strategy involving bundling and relying on brand loyalty.

Advertisement

Related Content

Actelion Could Succumb To Big Pharma's Charms
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Stockwatch: Earnings Season Inevitabilities
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study
J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Biosimilar Confidence And Knowledge Needed In Europe, Say Experts
Remsima Stars In Orion Pharma’s First Half
Bundled Contracts To Defend Against Biosimilars May Face Payer Skepticism

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel